KLOW80 China Fast Delivery High purity Peptide Factory 99% 80mg*10vials

  Product Detail  

Name:KL80 80mg

CAS No.: 89030-95-5

Purity: >99% (or refer to the Certificate of Analysis)

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Shelf Life: >2 years if stored properly

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

TB500 is a synthetic peptide fragment of human Thymosin Beta-4, a potent actin-regulating protein. It features a purity of ≥98% (HPLC) and is supplied as a sterile, white lyophilized powder. Primarily designed for research use, it promotes cell migration, angiogenesis, collagen deposition, and tissue repair by binding to actin and modulating cellular repair pathways. It is water-soluble after reconstitution, stable at -20°C, and packaged in sealed vials for laboratory investigation.

Production：
Manufactured via solid-phase peptide synthesis (SPPS), followed by purification and lyophilization to obtain the final product.

NOTE: This product was prepared by chemical synthesis. Used only for research. Not for human use.

Tirzepatide (M-ounjaro) is a novel medication indicated as an adjunct to diet and exercise in the treatment of patients with type 2 diabetes mellitus. Tirzepatide is a dual receptor agonist, acting on glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) to lower blood glucose levels.
  Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 agonist that has been studied recently as a treatment for patients with noncirrhotic NASH (SYNERGY-NASH, NCT04166773) given its association with significant weight loss and improvement in features of metabolic syndrome in diabetes trials.

 Retatrutide     (LY3437943) acetate is a triple agonist peptide for the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R).

Retatrutide acetate inhibits human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643, and 0.775 nM, respectively. It exhibits activity on mouse GCGR, GIPR, and GLP-1R with EC50 values of 2.32, 0.191, and 0.794 nM, respectively.

In vivo, Retatrutide (LY3437943) acetate engages with GCGR and enhances glucose tolerance in an ipGTT by acting through GIP or GLP-1 receptors. Activation via the glucagon receptor by Retatrutide acetate leads to significant weight reduction and increased energy expenditure. Retatrutide acetate can be utilized in research related to obesity.

Product Function

  The addition of GIP which anatagonizes the central effects of GLP-1 to cause nausea is designed to improve tolerability and also allow for more aggressive dosing with increased systemic exposure. A recent post-hoc analysis showed significantly decreased NASH-related biomarkers and increased adiponectin in patients with T2DM

  The weight-reducing actions of the GIPR-GLP1R co-agonist tirzepatide.Considerable interest is focused on the mechanisms of action of tirzepatide, a highly effective GIPR-GLP1R co-agonist that produces superior reductions in HbA1c and body weight, relative to that achieved with 1 mg once weekly of semaglutide in people with T2D. The GIPR is expressed in multiple regions of the mouse and human brain, in subsets of neurons and glial cells, with some hypothalamic and hindbrain cells exhibiting co-expression of the GIPR and GLP1R. Chemogenetic activation of GIPR + cells in the mouse hypothalamus acutely reduced food intake; however, co-administration of exendin-4 did not produce an additive reduction of food intake when compared to either intervention alone.

  Therapy with tirzepatide, 5-15 mg once weekly produces 8-12% body weight reduction in people with T2D, prompting ongoing development of tirzepatide as a weight loss agent for people with overweight or obesity. The importance of GIP for the weight loss properties of tirzepatide in humans is uncertain; however, tirzepatide failed to reduce body weight in Glp1r−/- mice, implicating a dominant role for the GLP1R in the weight loss observed with this agent. Glucose-dependent insulinotropic polypeptide (GIP) has been shown to reduce the extent of aversive responses induced by GLP-1 in mice and rats and decrease nausea and vomiting in the shrew.

Product Application

•1.Helps slow food leaving your stomach
• 2.Helps prevent your liver from making too much sugar
• 3.Helps the pancreas produce more insul when your blood sugar levels are high
• 4.Can help control blood glucose
• 5.Can reduce hyperglycemia, especially after meals
• 6.Can reduce fasting insul and fasting glucose
• 7.Can reduce hemoglobin A1c
• 8.Can decrease appetite and caloric intake, while inhibiting weight gain
• 9.Has been shown to lower triglyceride levels and oxidative stress from high LDL

Peptide Storage Guidelines: General Tips
When storing peptides, remember to:
• Store peptide in a cold, dry, dark place
• Avoid repeated freezing and thawing of peptide
• Avoid overexposure to the air
• Avoid light exposure
• Avoid storing peptides in solution long term
• Aliquot peptide according to experimental requirements